Briacell Therapeutics Corp (CVE:BCT) Director Rahoul Sharan sold 106,000 shares of the business’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of C$0.13, for a total transaction of C$13,780.00.
Shares of Briacell Therapeutics Corp (CVE:BCT) traded up C$0.01 during trading hours on Friday, hitting C$0.13. 616,500 shares of the stock traded hands, compared to its average volume of 159,749. Briacell Therapeutics Corp has a 52 week low of C$0.10 and a 52 week high of C$0.23. The firm has a market cap of $12.93, a P/E ratio of -4.33 and a beta of 0.80.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3272796/briacell-therapeutics-corp-bct-director-rahoul-sharan-sells-106000-shares-of-stock.html.
About Briacell Therapeutics
BriaCell Therapeutics Corp is Canada-based immuno-oncology Biotechnology Company, which is developing Bria-IMT, a targeted immunotherapy for the treatment of breast cancer. Bria-IMT has demonstrated Phase-I safety and efficacy data in patients with advanced breast cancers and is conducting a Phase I/IIa clinical trial for Bria-IMT.
Receive News & Ratings for Briacell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Briacell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.